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Abstract
Tropodithietic acid (TDA) is a structurally unique sulfur-containing antibiotic from the Roseobacter clade bacterium Phaeobacter
inhibens DSM 17395 and a few other related species. We have synthesised several structural analogues of TDA and used them in
bioactivity tests against Staphylococcus aureus and Vibrio anguillarum for a structure–activity relationship (SAR) study, revealing
that the sulfur-free analogue of TDA, tropone-2-carboxylic acid, has an antibiotic activity that is even stronger than the bioactivity
of the natural product. The synthesis of this compound and of several analogues is presented and the bioactivity of the synthetic
compounds is discussed.
Introduction
Tropodithietic acid (TDA, 1a) is an antibiotic produced by the
marine bacterium Phaeobacter inhibens. It has an unusual
structure that is made up by a dithiet moiety fused to tropone-2-
carboxylic acid (Figure 1) [1]. In Phaeobacter the compound is
accompanied by hydroxy-TDA 2 ,  while its tautomer
thiotropocin (1b) was previously reported from Pseudomonas
[2,3]. The biosynthesis of 1 starts from phenylalanine and
requires the paaABCDE and paaG genes of the upper phenyl-
acetic acid (PAA) catabolon [4,5], the six genes tdaABCDEF
that are located on a plasmid [6,7], and the adjacent paaZ2 gene
[8], a mutated copy of paaZ from the PAA catabolon. Particu-
larly interesting is the mechanism of sulfur introduction that we
have recently investigated in a study combining gene knock-
outs and feeding experiments with 34S-labelled amino acids [8].
In this study we could show that S-thiocysteine is the direct
sulfur precursor of TDA. The introduction of sulfur proceeds
via nucleophilic attack of S-thiocysteine to the Michael acceptor
of tropone-2-carboxylic acid coenzyme A ester and oxidative
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Scheme 1: Synthesis of tropone-2-carboxylic acid (13).
elimination of cysteine. The second sulfur atom is introduced by
analogous attack to the vinylogous Michael acceptor. The
volatiles tropone (3) and tropone hydrate 4 can also be detected
in P. inhibens headspace extracts and are shunt products of the
TDA biosynthetic pathway [9]. Clardy and coworkers have
recently reported on a series of structurally related compounds
with algicidal activity, represented by roseobacticide A (5), but
their biosynthesis is unknown [10].
Figure 1: TDA and related natural products from Phaeobacter
inhibens.
TDA exhibits a strong antibiotic activity against a broad spec-
trum of bacteria including alpha- and gammaproteobacteria,
flavobacteria and actinobacteria [11], but not against the
eukaryotic model organisms Artemia sp. and Caenorhabditis
elegans, suggesting P. inhibens or other TDA-producing
bacteria from the Roseobacter clade as promising candidates to
be used as probiotics in aquacultures [12]. The mode of action
of TDA is unknown, but it is difficult to select resistant and
tolerant strains from long-term exposures to sub inhibitory
concentrations of TDA, suggesting that TDA may interact with
several targets [13]. Here we report on the synthesis and bioac-
tivity of several TDA analogues for investigating the
structure–activity relationship (SAR) of this unique marine
antibiotic.
Results and Discussion
Synthesis of analogues of tropodithietic acid
For a detailed SAR study we first aimed at a series of com-
pounds with a seven-membered carbocyclic core and an overall
simplified structure as compared to the antibiotic TDA. There-
fore, tropone-2-carboxylic acid (13), lacking the unprecedented
dithiet moiety of TDA, was synthesised according to Scheme 1.
Cyclohexenone 6 was first converted with NaHMDS and
TMSCl into the corresponding silylenol ether that upon oxi-
dation with m-CPBA under migration of the TMS group yielded
the protected hydroxy ketone 7. Aldol reaction with tert-butyl
acetate to 8a and deprotection with TBAF gave 9a in 24% yield
over four steps. Oxidative cleavage of the glycol with NaIO4
resulted in a β-ketoester aldehyde that upon treatment with
silica gel underwent an intramolecular aldol condensation to a
mixture of 10a and 11a that were separable by column chroma-
tography. Oxidation with DDQ gave tert-butyl tropone-2-
carboxylate (12a) that was efficiently converted into 13 by stir-
ring in TFA. The synthesis of 12a followed a previously
published route for ethyl tropone-2-carboxylate (12b) [14], but
saponification of this ester led to decomposition, and therefore,
the tert-butyl ester 12a was prepared that allowed for a conver-
sion into 13 under acidic conditions.
Furthermore, a series of TDA analogues all with a seven-
membered carbocyclic core bearing a carbonyl function, a
carboxylic acid or ester function in 2-position, and various func-
tional groups such as halogen atoms and methoxy groups was
synthesised (Scheme 2). Acrolein (14) was reacted with tert-
butyl acetate (15) and LDA to yield the aldol product 16 that
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Scheme 2: Synthesis of halogenated TDA analogues.
was subsequently oxidised to the β-keto ester 17 in a Jones oxi-
dation. Treatment of the latter with TMSCl, imidazole and
DMAP resulted in 18 as a 3:2 mixture of two diastereomers that
proved to be unstable. However, the crude product was suffi-
ciently pure for its direct usage in a Diels–Alder reaction with
tetrachlorocyclopropene, resulting in the adduct 19 as a single
stereoisomer. The formation of only one stereoisomer is
explainable by an E/Z isomerisation of 18 and a Diels–Alder
reaction that only proceeds from (Z)-18, but not from (E)-18.
Treatment of 19 with TBAF resulted in cleavage of the TMS
protecting group followed by instantaneous elimination of HCl
under cyclopropane ring opening to 20 with 16% yield. Further-
more, similar amounts of the fluorinated derivative 21 (17%)
were isolated. Its formation is explained by the nucleophilic
attack of fluoride to the Michael acceptor in 20 followed by
elimination of chloride. In contrast, treatment of 19 with potas-
sium carbonate in MeOH yielded only minor amounts of 20 and
the substitution product, methoxy derivative 22, as main prod-
uct. All three compounds 20–22 were treated under various oxi-
dation conditions (including DDQ, IBX, SeO2, and MnO2) to
install the tropone moiety by dehydrogenation, but unfortu-
nately all these reaction conditions failed. Compound 22 was
subsequently converted into the free acid 23 by treatment with
TFA, while similar conversions of 20 and 21 were unsuccessful
due to the instability of the products.
Two structurally related halogenated compounds lacking the
carboxylic acid function as in TDA, 2,3,4-trichlorotropone (24)
and 3,4,5-trichloro-6,7-dihydrotropone (25), were prepared
through a known route (Scheme 3) [15]. Finally, a few cyclo-
heptanone derivatives with rigorously simplified structures as
compared to TDA were included in this study. The β-ketoester
27 containing a Michael acceptor was synthesised from methyl
cycloheptanone-2-carboxylate (26) by oxidation with Cu(OAc)2
and Pb(OAc)2 according to a known procedure [16]. The com-
pound cyclohept-2-en-1-one (28) is commercially available,
while we have previously reported the synthesis of cyclohept-4-
en-1-one (29) that was identified in headspace extracts from
streptomycetes [17].
Bioactivity tests
All synthetic compounds were screened in bioactivity tests
towards two bacterial strains, the Gram-positive Staphylo-
coccus aureus 8325 and the Gram-negative Vibrio anguillarum
90-11-287 (Table 1). These organisms were selected for our
bioactivity tests, because S. aureus is a clinically important
human pathogen and strains with resistances against multiple
antibiotic drugs cause severe problems with nosocomial infec-
tions. The bioactivity against V. anguillarum is interesting from
an ecological point of view, because P. inhibens was originally
isolated from scallop rearings [18-20], suggesting that the
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Table 1: Bioactivity tests with TDA and TDA analogues.
Compounda Staphylococcus aureus 8325 Vibrio anguillarum 90-11-287
MIC/mg L−1 MIC/μM MIC/mg L−1 MIC/μM
1 7.8 39 3.9 19
10a inactive 125 600
10b 125 700 125 700
11a inactive 125 600
12a 125 600 125 600
12b 125 700 125 700
13 3.9 26 1.0 6.5
20 inactive inactive
21 125 430 125 430
22 inactive inactive
23 inactive inactive
24 inactive 125 720
25 7.8 45 15.6 89
26 inactive inactive
27 62.5 370 46.9 280
28 62.5 570 31.3 280
29 62.5 570 31.3 570
aMICs were determined using the microdilution method according to guidelines of the Clinical and Laboratory Standards Institute [21]. Compounds
with MICs > 125 mg L−1 were regarded as inactive.
Scheme 3: Further compounds included in this SAR study.
natural function of P. inhibens may be to prevent molluscs from
Vibrio infections.
Most of the compounds tested had minimal inhibitory concen-
trations (MICs) exceeding that of TDA, however, two com-
pounds were of equal or even better antibiotic activity. Com-
pound 25 was as effective, and tropone-2-carboxylic acid (13),
closely resembling the structure of TDA, but lacking its sulfur
atoms, was even more effective with a MIC corresponding to
half the MIC of TDA (MIC against S. aureus was 26 μM versus
39 μM, while the MIC against V. anguillarum was 6.5 μM
versus 19 μM). This indicates that the dithiet moiety of TDA is
not essential for the direct antibacterial effect of the compound,
and may have other physiological or ecological functions. This
result is particularly surprising, because the coenzyme A ester
of 13 is an intermediate along the biosynthetic pathway to TDA,
so the question arises what may have been the evolutionary
advantages of extending the biosynthetic pathway from the
coenzyme A ester of 13 to TDA by the introduction of two
sulfur atoms. A possible answer may be that TDA has more or
other targets than 13 which may have the consequence that the
development of resistances against TDA is prevented, thus
offering an evolutionary advantage.
Conclusion
We have synthesised a series of compounds with seven-
membered carbocyclic rings. Their structures were inspired by
the antibiotic TDA from the marine bacterium P. inhibens. One
compound, 3,4,5-trichloro-5,6-dihydrotropone (25), showed a
strong antibiotic activity against S. aureus and V. anguillarum
that is similar to the activity of TDA, while tropone-2-
carboxylic acid (13) had an even stronger antibiotic effect. This
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suggests that the sulfur atoms in TDA are not essential for
bioactivity, but different modes of action for TDA and its
sulfur-free analogue cannot be excluded.
Experimental
Bioactivity testing. All synthetic compounds were used in
bioactivity tests towards two bacterial strains, Staphylococcus
aureus 8325 [22] and Vibrio anguillarum 90-11-287 [23]
(Table 1). The two strains were grown as precultures overnight
with agitation at 25 °C in 20 mL cation-adjusted Mueller Hinton
II Broth (Cat. No. 297963, Becton, Dickinson and Company,
Sparks, MD, USA). The minimum inhibitory concentration
(MIC) of the compounds was determined using the microdilu-
tion method according to the guidelines of the Clinical and
Laboratory Standards Institute (CLSI 2006) [21]. All com-
pounds were dissolved in DMSO to stock solutions of 1.5 g L−1
and further diluted in the bacterial growth medium, Mueller
Hinton II Broth. Final concentrations ranging from 500 to
0.5 mg L−1 were tested and solvent controls were included.
Supporting Information
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